LIVIVO - Search results -

Search results

Result 1 - 10 of total 113

Search options

Conference proceedings: Großzehengrundgelenksarthrodese mittels humanem kortikalen Knochentransplantat (Shark Screw®)

Hanslik-Schnabel, Beatrice / Zöchling, Christoph / Schanda, Jakob

2022 , Page(s) AB36–692

Event/congress	Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2022); Berlin; ; Berufsverband für Orthopädie und Unfallchirurgie; 2022
Keywords	Medizin, Gesundheit ; Hallux ; kortikale Knochenschraube ; Shark Screw® ; Arthrodese ; Großzehengrundgelenk ; Metatarsophalangealgelenks ; MTPG1 ; retrospektive Studie
Publishing date	2022-10-25
Publisher	German Medical Science GMS Publishing House; Düsseldorf
Document type	Conference proceedings
DOI	10.3205/22dkou231
Database	German Medical Science

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S).

Zochling, Jane

Arthritis care & research

2011 Volume 63 Suppl 11, Page(s) S47–58

MeSH term(s)	Health Status Indicators ; Humans ; Quality of Life/psychology ; Severity of Illness Index ; Spondylitis, Ankylosing/diagnosis ; Spondylitis, Ankylosing/psychology ; Surveys and Questionnaires/standards
Language	English
Publishing date	2011-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	645059-3
ISSN	2151-4658 ; 0893-7524 ; 2151-464X
ISSN (online)	2151-4658
ISSN	0893-7524 ; 2151-464X
DOI	10.1002/acr.20575
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2446: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Usability of the Certolizumab Pegol Auto-Injection Device in Australian Patients with Chronic Rheumatic Diseases: Results from a Market Research Study.

Aw, Juan / Griffiths, Hedley / Zochling, Jane / Lanzafame, Alfred / Jordan, Andrew

Patient preference and adherence

2021 Volume 15, Page(s) 1469–1476

Abstract: Purpose: To determine the usability of the ergonomically designed certolizumab pegol pre-filled pen (CZP PFP) in Australian patients with active ankylosing spondylitis, active psoriatic arthritis or moderate-to-severe rheumatoid arthritis.: Patients ... ...

Abstract	Purpose: To determine the usability of the ergonomically designed certolizumab pegol pre-filled pen (CZP PFP) in Australian patients with active ankylosing spondylitis, active psoriatic arthritis or moderate-to-severe rheumatoid arthritis. Patients and methods: CZP-naive patients were recruited from six clinical centers in Australia between November 2018 and May 2019. Patients and healthcare professionals (HCPs) reviewed training materials and completed pre-injection surveys; patients then self-administered ≥1 injection with the CZP PFP during each of three visits. Patients and HCPs then completed post-injection surveys. Some survey questions were adapted from the self-injection assessment questionnaire (SIAQ Results: Seventy patients participated (65 completed 3 visits); 33 were biologic-experienced. All patients agreed that training materials were informative; 94% found them easy to understand. Pre-injection, 89% of patients reported little or no anxiety about having injections; 67% (79% in biologic-experienced) were very confident about self-injecting the correct dose with the PFP. Ninety percent of patients were satisfied/very satisfied with their first experience with the CZP PFP; those with pre-injection anxiety reported lower satisfaction (43% vs 79% "very satisfied"). Confidence and satisfaction increased as visits progressed (for Visit 3 vs Visit 2: 69% vs 56% "very convenient"; 75% vs 67% "very confident"; 71% vs 57% "very satisfied"). All HCPs were confident in their patients' competence to self-inject and thought all patients had overall positive experiences. Conclusion: Australian patients with chronic rheumatic disease reported high levels of confidence and satisfaction following initial use of the CZP PFP. The availability of devices with patient-centered design innovations may help overcome barriers to self-injection for improved adherence/outcomes.
Language	English
Publishing date	2021-06-29
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2455848-5
ISSN	1177-889X
ISSN	1177-889X
DOI	10.2147/PPA.S310086
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Assessment and treatment of ankylosing spondylitis: current status and future directions.

Zochling, Jane

Current opinion in rheumatology

2008 Volume 20, Issue 4, Page(s) 398–403

Abstract: Purpose of review: To summarize the latest developments in outcome assessment and treatment in ankylosing spondylitis.: Recent findings: A number of clinical and radiological outcome measures used in the assessment of patients with ankylosing ... ...

Abstract	Purpose of review: To summarize the latest developments in outcome assessment and treatment in ankylosing spondylitis. Recent findings: A number of clinical and radiological outcome measures used in the assessment of patients with ankylosing spondylitis have recently been critically reappraised and compared, to assist in the interpretation of study results and to guide choices for outcome measures in clinical trials. Clinical tools for assessing spinal mobility, peripheral joint disease and enthesitis, and radiograph and MRI scoring methods have been reviewed for validity and test performance in patients with ankylosing spondylitis. Experience with the use of anti-tumour necrosis factor-alpha therapies for ankylosing spondylitis continues to grow, and longer term data show these treatments continue to be effective and safe to 5 years of therapy. Summary: As measurement tools for disease state and progression in ankylosing spondylitis are refined, the assessment of response to therapy improves, with the aim that real effect on structural damage in ankylosing spondylitis may be detected.
MeSH term(s)	Humans ; Spondylitis, Ankylosing/diagnosis ; Spondylitis, Ankylosing/drug therapy
Language	English
Publishing date	2008-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1045317-9
ISSN	1531-6963 ; 1040-8711
ISSN (online)	1531-6963
ISSN	1040-8711
DOI	10.1097/BOR.0b013e3283028328
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3028: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Octanorm [cutaquig®], a new immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg/mL) - Biochemical characterization, pathogen safety, and stability.

Gelbmann, Nicola / Zöchling, Alfred / Pichotta, Alexander / Schmidt, Torben / Murányi, Andrej / Ernegger, Thomas / Pock, Katharina / Römisch, Jürgen

Biologicals : journal of the International Association of Biological Standardization

2019 Volume 60, Page(s) 60–67

Abstract: Octanorm (marketed as cutaquig® in Canada and US [2018] and registered in several European countries [2019]) is a new immunoglobulin subcutaneous 16.5% liquid for the treatment of patients with primary immune deficiency (PID) and secondary immune ... ...

Abstract	Octanorm (marketed as cutaquig® in Canada and US [2018] and registered in several European countries [2019]) is a new immunoglobulin subcutaneous 16.5% liquid for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) depending on country's specific indications. Octanorm contains ≥96% human IgG and is characterized by especially low concentrations of polymers and aggregates, IgA and IgM, a physiological osmolality along with a low isoagglutinin titer. The Octanorm manufacturing process is based on the well-established IVIG octagam® 5% and 10% process, but yields a higher immunoglobulin concentration of 16.5% in the final product. Octanorm shows a distribution of immunoglobulin G subclasses closely proportional to native human plasma and comprises a broad spectrum of antibodies against infectious agents. Potential procoagulant activity is not detectable. IgG functionality and physico-chemical integrity have been demonstrated by state-of-the-art-methods. The virus safety of Octanorm is ensured via a combination of three validated independent methods as part of the manufacturing process. Substantial prion depletion during the manufacturing process has also been demonstrated. Compared with other commercially available subcutaneous immunoglobulin (SCIG) 20% products, Octanorm 16.5% shows a lower viscosity, which is a valuable feature that allows for a more comfortable infusion experience.
MeSH term(s)	Adult ; Biomarkers, Pharmacological ; Drug Stability ; Female ; Humans ; Immunoglobulin G/chemistry ; Immunoglobulin G/therapeutic use ; Immunologic Deficiency Syndromes/drug therapy ; Infusions, Subcutaneous
Chemical Substances	Biomarkers, Pharmacological ; Immunoglobulin G
Language	English
Publishing date	2019-06-01
Publishing country	England
Document type	Journal Article
ZDB-ID	1017370-5
ISSN	1095-8320 ; 1045-1056
ISSN (online)	1095-8320
ISSN	1045-1056
DOI	10.1016/j.biologicals.2019.05.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 879: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Mortality in rheumatoid arthritis and ankylosing spondylitis.

Zochling, J / Braun, J

Clinical and experimental rheumatology

2009 Volume 27, Issue 4 Suppl 55, Page(s) S127–30

Abstract: The rheumatic diseases not only bring pain, disability and poorer quality of life, but also a premature mortality which is often overlooked. Alongside mortality due to the direct complications of disease comes an increase in deaths related to specific ... ...

Abstract	The rheumatic diseases not only bring pain, disability and poorer quality of life, but also a premature mortality which is often overlooked. Alongside mortality due to the direct complications of disease comes an increase in deaths related to specific therapies and indirect causes such as cancer and cardiovascular mortality. By comparing mortality and its causes in two of the most common inflammatory arthritides, rheumatoid arthritis and ankylosing spondylitis, common threads emerge which give us insight into the impact of chronic inflammatory disease and new directions for patient management.
MeSH term(s)	Antirheumatic Agents/adverse effects ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/mortality ; Comorbidity ; Humans ; Iatrogenic Disease/epidemiology ; Population Surveillance ; Risk Factors ; Spondylitis, Ankylosing/drug therapy ; Spondylitis, Ankylosing/mortality ; Survival Rate
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2009-07
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Seronegative spondyloarthritis.

Zochling, Jane / Smith, Emma U R

Best practice & research. Clinical rheumatology

2010 Volume 24, Issue 6, Page(s) 747–756

Abstract: Seronegative spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases with common clinical and aetiological features, including axial and peripheral inflammatory arthritis, enthesitis, extra-articular manifestations and a close link to the ... ...

Abstract	Seronegative spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases with common clinical and aetiological features, including axial and peripheral inflammatory arthritis, enthesitis, extra-articular manifestations and a close link to the presence of the human leucocyte antigen (HLA)-B27 epitope. Ankylosing spondylitis is the most common of the SpA diseases, with prevalence in the Caucasian population ranging between 0.15% and 1.8%, generally higher in populations with a higher background prevalence of HLA-B27 positivity. Incidence has been estimated between 0.49 (Japan) and 10 (Norway) per 100,000. The prevalence of psoriatic arthritis ranges from 0.02% to 0.2%, and the incidence in the normal population is 7.2 per 100,000 per year. In patients with existing psoriasis, the prevalence of psoriatic arthritis rises to 6-42%. The prevalence of reactive arthritis is dependent on the background incidence of gastrointestinal or genitourinary infections; incidence has been described as up to 30-40 per 100,000. SpA symptoms are present in up to 50% of patients with inflammatory bowel disease.
MeSH term(s)	Arthritis, Psoriatic/epidemiology ; Arthritis, Psoriatic/immunology ; Arthritis, Psoriatic/physiopathology ; Female ; HLA-B27 Antigen/analysis ; Humans ; Incidence ; Inflammatory Bowel Diseases/epidemiology ; Inflammatory Bowel Diseases/immunology ; Inflammatory Bowel Diseases/physiopathology ; Male ; Prevalence ; Spondylitis, Ankylosing/epidemiology ; Spondylitis, Ankylosing/immunology ; Spondylitis, Ankylosing/physiopathology
Chemical Substances	HLA-B27 Antigen
Language	English
Publishing date	2010-12
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2052323-3
ISSN	1532-1770 ; 1521-6942
ISSN (online)	1532-1770
ISSN	1521-6942
DOI	10.1016/j.berh.2011.02.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Se 1036: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Mortality in ankylosing spondylitis.

Zochling, J / Braun, J

Clinical and experimental rheumatology

2008 Volume 26, Issue 5 Suppl 51, Page(s) S80–4

Abstract: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease which causes pain along with loss of physical function and quality of life over many years. It has also been shown to increase mortality compared to the general population, ... ...

Abstract	Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease which causes pain along with loss of physical function and quality of life over many years. It has also been shown to increase mortality compared to the general population, independent of treatment modalities. Cardiovascular deaths are increased, and recent studies suggest both an abnormality of lipid regulation and microvascular changes. Increased rates of suicide, accidental death, and alcohol-related deaths have also been reported. This review examines rates and causes of increased mortality in AS and highlights a need to focus on cardiovascular risk factors and psychological health in addition to physical disability in patients with AS.
MeSH term(s)	Humans ; Iatrogenic Disease/epidemiology ; Pulmonary Fibrosis/complications ; Pulmonary Fibrosis/mortality ; Spondylitis, Ankylosing/complications ; Spondylitis, Ankylosing/mortality
Language	English
Publishing date	2008-09
Publishing country	Italy
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Quality indicators, guidelines and outcome measures in ankylosing spondylitis.

Zochling, J / Braun, J

Clinical and experimental rheumatology

2007 Volume 25, Issue 6 Suppl 47, Page(s) 147–152

Abstract: The challenge of managing knowledge is a difficult one, and it is no longer enough simply to conduct clinical trials. Quality of care requires the incorporation of research knowledge into clinical practice. As our knowledge of the chronic inflammatory ... ...

Abstract	The challenge of managing knowledge is a difficult one, and it is no longer enough simply to conduct clinical trials. Quality of care requires the incorporation of research knowledge into clinical practice. As our knowledge of the chronic inflammatory rheumatic disease ankylosing spondylitis (AS) has grown, evidence-based recommendations for the early diagnosis and management of AS and scientifically-derived outcome measures have been developed to aid the clinician at the point of care. Some of these, including the ASAS/EULAR recommendations for the management of AS, are now being validated in national and international studies. This article discusses existing recommendations and the need for specific quality indicators in the field of AS.
MeSH term(s)	Humans ; Medical Records ; Practice Guidelines as Topic ; Quality Indicators, Health Care ; Referral and Consultation ; Registries ; Spondylitis, Ankylosing/therapy ; Treatment Outcome
Language	English
Publishing date	2007-11
Publishing country	Italy
Document type	Journal Article
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Remission in ankylosing spondylitis.

Zochling, J / Braun, J

Clinical and experimental rheumatology

2006 Volume 24, Issue 6 Suppl 43, Page(s) S–88–92

Abstract: Remission is a major goal of medical therapy in chronic disease. Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the axial skeleton and other body structures, causing pain, stiffness, functional loss, and disability. ... ...

Abstract	Remission is a major goal of medical therapy in chronic disease. Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that affects the axial skeleton and other body structures, causing pain, stiffness, functional loss, and disability. Until recently only symptomatic therapies were available, and control was poor in patients with severe disease. However, the TNF antagonists have now changed this substantially. The concept of disease remission in AS has not received much attention in the current literature. There exists one set of partial remission criteria formally developed by the ASsessments in Ankylosing Spondylitis (ASAS) working group on the basis of clinical trials with nonsteroidal anti-inflammatory drugs for use in clinical trials. Furthermore, a state of low disease activity has been defined empirically in studies of anti-tumour necrosis factor (anti-TNF) therapy to describe clinically relevant treatment efficacy. As more effective therapies become available for AS, disease remission is increasingly regarded as an appropriate therapeutic goal that may then be translated into modification of progressive structural damage. There is a need to further define and evaluate current proposals concerning remission in AS.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; Clinical Trials as Topic ; Endpoint Determination ; Humans ; Practice Guidelines as Topic ; Remission Induction ; Severity of Illness Index ; Spondylitis, Ankylosing/drug therapy ; Spondylitis, Ankylosing/pathology
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2006-11
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	605886-3
ISSN	1593-098X ; 0392-856X
ISSN (online)	1593-098X
ISSN	0392-856X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2002: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito